SCHEMBL30140412

SCHEMBL30140412

Fc1cc2ncnc(Nc3ccc(OCC4CC4)c(F)c3F)c2nc1O[C@H]1CCNC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.43
EGFR P00533 12/20 0.43
FLT1 P17948 10/20 0.43
FGFR1 P11362 9/20 0.43
FLT4 P35916 9/20 0.43
RET P07949 2/20 0.38
EPHA2 P29317 6/20 0.37
EPHB4 P54760 3/20 0.37
PDGFRB P09619 2/20 0.36
TEK Q02763 2/20 0.36
ERBB2 P04626 2/20 0.36
BMPR1B O00238 1/20 0.36
PLK4 O00444 1/20 0.36
CIT O14578 1/20 0.36
GAK O14976 1/20 0.36
EPHB6 O15197 1/20 0.36
RIPK2 O43353 1/20 0.36
ROCK2 O75116 1/20 0.36
STK10 O94804 1/20 0.36
MAP4K4 O95819 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30140353 0.93 KDR (0.44) KDREGFRFLT1FGFR1FLT4
SCHEMBL30140210 0.92 EGFR (0.42) KDREGFRFLT1FGFR1FLT4
SCHEMBL30140239 0.92 EGFR (0.42) KDREGFRFLT1FGFR1FLT4
SCHEMBL30140076 0.88 EPHA2 (0.42) KDREGFRFLT1FGFR1FLT4
SCHEMBL30140218 0.88 EPHA2 (0.42) KDREGFRFLT1FGFR1FLT4
SCHEMBL30140086 0.87 EGFR (0.35) KDREGFRFLT1FGFR1FLT4
SCHEMBL30140107 0.87 EGFR (0.39) KDREGFRFLT1FGFR1FLT4
SCHEMBL30140339 0.86 EGFR (0.41) KDREGFRFLT1FGFR1FLT4
SCHEMBL23538163 0.83 EGFR (0.45) KDREGFRFLT1RETEPHA2
SCHEMBL23538160 0.83 EGFR (0.45) KDREGFRFLT1RETEPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022266426-A1 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed